Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
@inproceedings{Kowalec2017ApplicationOP, title={Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia}, author={Kaarina Kowalec and Elaine Kingwell and Robert Carruthers and Ruth Ann Marrie and Sasha Bernatsky and Anthony Traboulsee and Colin J. D. Ross and Bruce Carleton and Helen Tremlett}, booktitle={BMJ open}, year={2017} }
- Published 2017 in BMJ open
DOI:10.1136/bmjopen-2017-016276
INTRODUCTION
Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of multiple sclerosis (MS). The use of DMF in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol… CONTINUE READING
From This Paper
Figures, tables, and topics from this paper.
Figures & Tables
References
Publications referenced by this paper.
Showing 1-10 of 34 references
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
View 4 Excerpts
Highly Influenced